Expression of tyrosine kinase receptors in lung carcinoids

Tumor Biology

Volumn 27, Issue 3, 2006, Pages 153-157

  Granberg, Dan ^a   Wilander, Erik ^a   Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

c kit; Carcinoids; Epidermal growth factor receptor; Lung; PDGFR ; PDGFR ; Platelet derived growth factor; Tyrosine kinase receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLYCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

ARTICLE; BENIGN TUMOR; BRONCHUS CARCINOID; CANCER PATIENT; CANCER SURVIVAL; DRUG INDICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

EID: 33646474129     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092718     Document Type: Article

References (27)

1. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ: First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer 2001;37(suppl 1):S25-S29.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
3. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
4. Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, Capaldi A, Vietti-Ramus G, Alabiso O, Aglietta M: A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004;66:38-45.
5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantaijian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman SL, Capdeville R, Dimitrijevic S, Druker B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
8. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS: Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(suppl 5):S83-S87.
9. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga JRF, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-3825.
10. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
11. Santoro A, Cavina R, Latteri F, Zucali PA, Ginanni V, Campagnoli E, Ferrari B, Morenghi E, Pedicini V, Roncalli M, Alloisio M, Ravasi G, Soto Parra HJ: Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Ann Oncol 2004;15:33-37.
12. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G: Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control 2003;10:388-395.
13. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
14. Granberg D, Eriksson B, Wilander E, Grimfjärd P, Fjällskog ML, Öberg K, Skogseid B: Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001;12:1383-1391.
15. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: World Health Organization. Histological Typing of Lung and Pleural Tumours, ed 3. Berlin, Springer, 1999.
16. Fjällskog ML, Lejonklou MH, Öberg KE, Eriksson BK, Janson ET: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003;9:1469-1473.
17. Chaudhry A, Papanicolaou V, Öberg K, Heldin CH, Funa K: Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992;52:1006-1012.
18. Moody TW, Lee M, Kris RM, Bellot F, Bepler G, Oie H, Gazdar AF: Lung carcinoid cell lines have bombesin-like peptides and EGF receptors. J Cell Biochem 1990;43:139-147.
19. Nilsson O, Wängberg B, Kölby L, Schultz GS, Ahlman H: Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. Int J Cancer 1995;60:645-651.
20. Krishnamurthy S, Dayal Y: Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 1997;21:327-333.
21. Sampietro G, Tomasic G, Collini P, Biganzoli E, Boracchi P, Bidoli P, Pilotti S: Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis. Appl Immunohistochem Mol Morphol 2000;8:49-56.
22. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL: The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004;128:538-543.
23. Lonardo F, Pass HI, Lucas DR: Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 2003;11:51-55.
24. Pelosi G, Masullo M, Leon ME, Veronesi G, Spaggiari L, Pasini F, Sonzogni A, Iannucci A, Bresaola E, Viale G: CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch 2004;115:449-455.
25. Sawyers CL: Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev 2002;12:111-115.
26. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
27. Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, Weiss WA: Combinatorial efficacy achieved through two-point blockade within a signaling pathway - a chemical genetic approach. Cancer Res 2003;63:8930-8938.